MedTrace Logo

A Study Observing US Patients With HAE Type I or II Who Take Icatibant to Treat HAE Attacks

NCT07009262 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 88

Last updated 2026-01-13

No results posted yet for this study

Summary

Patients with HAE Type I or II who enroll in the study are asked to complete a patient diary when they experience an HAE attack. If icatibant is taken as the first treatment for the attack, the patient diary will ask questions over a 48 hour period after dosing to track the characteristics and severity of the attack along with the patient's level of anxiety.

Conditions

Interventions

OTHER

Inapplicable

Inapplicable

Sponsors & Collaborators

  • US Hereditary Angioedema Association

    collaborator UNKNOWN

  • KalVista Pharmaceuticals, Ltd.

    lead INDUSTRY

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-21
Primary Completion
2025-11-25
Completion
2025-11-25

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07009262 on ClinicalTrials.gov